Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses.

Weigel BJ, Panoskaltsis-Mortari A, Diers M, Garcia M, Lees C, Krieg AM, Chen W, Blazar BR.

Exp Hematol. 2006 Oct;34(10):1403-12.

PMID:
16982333
2.

Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice.

DeMatos P, Abdel-Wahab Z, Vervaert C, Hester D, Seigler H.

J Surg Oncol. 1998 Jun;68(2):79-91. Review.

PMID:
9624036
3.

Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.

Morisaki T, Matsumoto K, Onishi H, Kuroki H, Baba E, Tasaki A, Kubo M, Nakamura M, Inaba S, Yamaguchi K, Tanaka M, Katano M.

Hum Cell. 2003 Dec;16(4):175-82. Review.

PMID:
15147037
4.

Cancer vaccines based on dendritic cells loaded with tumor-associated antigens.

Burdin N, Moingeon P.

Cell Biol Toxicol. 2001;17(2):67-75. Review.

PMID:
11499697
5.

Dendritic cell-tumor fusion vaccines for renal cell carcinoma.

Avigan D.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6347S-52S. Review.

6.

Chaperone-rich cell lysates, immune activation and tumor vaccination.

Zeng Y, Graner MW, Katsanis E.

Cancer Immunol Immunother. 2006 Mar;55(3):329-38. Epub 2005 May 11. Review.

PMID:
15887013
7.

Vaccination therapy with tumor-dendritic cell hybrids: a promising therapeutic approach?

Haenssle HA.

Curr Opin Investig Drugs. 2005 Dec;6(12):1240-5. Review.

PMID:
16370389
8.

Loading DCs with Ag.

Vari F, Hart DN.

Cytotherapy. 2004;6(2):111-21. Review.

PMID:
15203987
9.

Dendritic cell vaccination: new hope for the treatment of metastasized endocrine malignancies.

Schott M, Seissler J.

Trends Endocrinol Metab. 2003 May-Jun;14(4):156-62. Review.

PMID:
12714275
10.

Dendritic cells as vectors for immunotherapy of cancer.

Paczesny S, Ueno H, Fay J, Banchereau J, Palucka AK.

Semin Cancer Biol. 2003 Dec;13(6):439-47. Review.

PMID:
15001163
11.
12.

The immune response to breast cancer, and the case for DC immunotherapy.

Allan CP, Turtle CJ, Mainwaring PN, Pyke C, Hart DN.

Cytotherapy. 2004;6(2):154-63. Review.

PMID:
15203992
13.

[Exosomes derived from dendritic cells].

Amigorena S.

J Soc Biol. 2001;195(1):25-7. Review. French.

PMID:
11530496
14.
15.

Cellular immunotherapy with dendritic cells in cancer: current status.

Nencioni A, Brossart P.

Stem Cells. 2004;22(4):501-13. Review.

16.

Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters.

Nakai N, Hartmann G, Kishimoto S, Katoh N.

Pigment Cell Melanoma Res. 2010 Oct;23(5):607-19. doi: 10.1111/j.1755-148X.2010.00736.x. Epub 2010 Jul 27. Review.

PMID:
20579307
17.

Dendritic cell vaccines in the treatment of multiple myeloma: advances and limitations.

B├╝chler T, Hajek R.

Med Oncol. 2002;19(4):213-8. Review.

PMID:
12512914
18.

Dendritic cell-based immunotherapy in multiple myeloma.

Yi Q.

Leuk Lymphoma. 2003 Dec;44(12):2031-8. Review.

PMID:
14959845
19.

DC-based cancer vaccines: lessons from clinical trials.

Brody JD, Engleman EG.

Cytotherapy. 2004;6(2):122-7. Review. No abstract available.

PMID:
15203988
20.

Migration of dendritic cell based cancer vaccines: in vivo veritas?

Adema GJ, de Vries IJ, Punt CJ, Figdor CG.

Curr Opin Immunol. 2005 Apr;17(2):170-4. Review.

PMID:
15766677

Supplemental Content

Support Center